Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

Publication | Closed Access

DOI

459

Citations

References

2010

Year

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López, Norma C. Gutiérrez, Ana-Isabel Teruel, Raquel de Paz, José García‐Laraña, Enrique Garcíá Bengoechea, Alejandro Martı́n, Joaquín Díaz Mediavilla,

The Lancet Oncology

Hematological MalignancyElderly PatientsMedicineRandomised TrialHematologyPharmacologyPrednisone Versus BortezomibPharmacotherapyOncologyMyeloid Neoplasia